We are proud to announce the latest impact factors (IFs) for the British Society for Immunology’s official journals: Clinical & Experimental Immunology has achieved an IF of 4.330 and Immunology* has reached its highest-ever IF of 7.397.
We’d like to take this opportunity to celebrate our journals for building upon their position as highly-respected publications within the field of immunology. Immunotherapy Advances, our first fully Open Access journal launched last year, has recently celebrated its indexing in the Directory of Open Access Journals.
We’d like to thank our editorial teams, led by Editors-in-Chief Professor Leonie Taams, Professor Simon Milling and Professor Tim Elliott, for their ongoing commitment to the journals, and everyone who has contributed to the continued success of our journals, including authors, readers, reviewers and editors.
Whilst we are aware that the impact factor has certain limitations, we take this as one measure of the high-quality work submitted by our authors, contributing highly-cited reviews and research, which we have highlighted here.
We are continuing to achieve our goal of publishing content that is timely and relevant to our research community, as demonstrated by the high Altmetric scores and downloads of our articles.
We would also like to take this opportunity to highlight other successes from our journals:
- Acceptance rate: 80%
- Time to first decision: 21.8 days
- Time to final decision: 37.6 days
Clinical & Experimental Immunology
- Mean time to first decision: 15.8 days
- Mean time to final decision: 32.1 days
- Average monthly usage: 78,100 full-text downloads
- 5-year impact factor: 4.303
- Immediacy index: 1.445
- Mean time to first decision: 15.4 days
- Mean time to final decision: 25 days
- Average monthly usage: 72,700 full-text downloads
- 5-year impact factor: 5.784
- Immediacy index: 2.794
You can find more information about our journals here: Clinical & Experimental Immunology, Immunotherapy Advances and Immunology. We offer a broad suite of additional benefits to authors, including a very rapid time to first decision, live Altmetric tracking on your articles, no page or colour charges for members, integration with Publons, and the skills of a dedicated marketing team who will promote your article to interested parties.
Profits derived from the sale of the journals are invested back into the BSI to benefit our members in the form of grants, travel awards, Regional and Affinity Group meetings, our popular Congress and other key initiatives. We encourage you to support the BSI by submitting your work.
*Please note that from 2022 the journal Immunology will no longer be affiliated with the British Society for Immunology and as such, the profits derived from the journal will no longer contribute to the Society. Read the full announcement from BSI President, Professor Arne Akbar. If you have any questions about how these changes will affect you, please take a look at our FAQs.